MERIT Trial Leaves Role of Pfizer’s Celsentri Unclear

With Pfizer’s novel HIV treatment Celsentri failing to demonstrate non-inferiority to Bristol-Myers Squibb’s Sustiva in the MERIT trial, the drug’s chances of easily securing a first-line use indication look rather bleak.
Pharmaceutical Business Review